anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
PURPOSE: To industrially and advantageously obtain the subject compound useful as a therapeutic agent, etc., for ovarian, mammary cancer, lung cancers, etc., by culturing a cell or a tissue of a plant capable of producing a taxane type diterpene in the presence of an oxidizing agent and recovering the produced oil from the resultant cultured product. CONSTITUTION: A cell or a tissue of a plant capable of producing a taxane type diterpene (e.g. Taxus baccata Linn) is bedded on a solid culture medium containing naphthaleneacetic acid and cultured in the dark at 25 deg.C by stationary culture to produce a callus, which is then cultured in a culture medium containing an oxidizing agent (e.g. potassium peroxodisulfate) at 25 deg.C for 21 days by shaking culture, then collecting the cultured cell of the plant capable of producing the taxane type diterpene by filtration, freeze-drying the collected cell, extracting the dried callus and culture medium with methanol, dichloromethane, etc., and purifying the extract by a high-performance liquid chromatography. Thereby, the objective taxane type diterpene (e.g. taxol) useful as a therapeutic agent, etc., for ovarian, mammary, lung cancers, etc., is efficiently obtained.
FIELD: pharmacology. SUBSTANCE: method deals with obtaining antitubercular preparation of wide spectrum of pharmacological action: restorative, antiphlogistic, antimicrobial, antihypoxic, gastroprotective, immunomodelling, hepatoprotective, antiproliferative, antiexudative, antioxidant, in particular. Islacet preparation consists of alcoholic and aqueous extract and contains extractive substances of lichen thallus of Cetraria islandica (L. ) Ach., polysaccharides and lichen acids, among them. It is, also, suggested the method to obtain Islacet medicinal preparation. Plant raw material before extraction should be pre-reduced, extraction is carried out due to fractional maceration or percolation by using ethanol of different concentration or with purified water followed by thickening alcoholic or aqueous extract and its drying. The present method provides maximum isolation of substances, and, also, keeping biologically active substances (polysaccharides, lichen acids) for prolonged period of time. Islacet preparation improves oxygen assimilation by tissues stimulating immune system in tuberculosis-suffering patients. EFFECT: higher efficiency of prophylaxis and therapy. 8 cl, 8 ex, 7 tbl
ELLENCE (epirubicin hydrochloride injection) is an anthracycline topoisomerase inhibitor for intravenous administration. ELLENCE is supplied as a sterile, clear, red solution and is available in polypropylene vials containing 50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride. Inactive ingredients include 9 mg sodium chloride, USP, and water for injection, USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid and/or sodium hydroxide, NF.

Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic derivative of daunorubicin. The chemical name is (8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L- arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride. The active ingredient is a red-orange hygroscopic powder, with the empirical formula C27 H29 NO11 HCl and a molecular weight of 579.95. The structural formula is as follows:
Cycles 1-6: Tipifarnib and Naxitamab Tipifarnib: on days 1-7 and 15-21 of each 28-day cycle. Naxitamab IV on Days 1, 3, and 5 of each cycle.
The aim of this Phase III, randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of denosumab (DMAb) in Chinese postmenopausal women with osteoporosis at increased risk of fracture. The study design consists of two phases: Screening and 12-month Double-Blind treatment phase. Following the Screening phase, all eligible subjects will be randomized to receive Double-Blind DMAb (60 mg) or Placebo study medication in a 3:1 ratio. DMAb 60 mg and placebo will be administered as a single subcutaneous (SC) injection at the beginning of the Double-Blind phase and at 6 months following the initial dose. All subjects will receive daily supplementation of oral elemental calcium (at least 600 mg) and vitamin D (at least 400 International Units \[IU\]). The primary objective is to determine the effects of DMAb compared to placebo with respect to mean percent change in BMD at the lumbar spine, as measured by dual-energy x-ray absorptiometry (DXA), from Baseline to Month 12. Secondary objectives include the evaluation between the DMAb and placebo treatment groups: change in BMD: at the lumbar spine (Month 6), total hip (Months 6 and 12), femoral neck (Months 6 and 12) and trochanter (Months 6 and 12); and serum biomarkers of bone formation and resorption (Months 6 and 12). Clinical safety of denosumab will also be assessed in this population.
Stroke remains a major global healthcare problem. Recent data compiled by the American Heart Association (AHA) for 2008 show that the annual incidence of new or recurrent stroke in the United States is about 780,000, with approximately 600,000 of these strokes being first attacks. Among adults age 20 and older, the estimated prevalence of stroke in 2005 was 5.8 million in the United States, resulting in \>150,000 deaths annually, with 4.8 million stroke survivors alive today. Stroke ranks as the country's third leading cause of death, behind only cancer and heart disease. The only approved treatments of acute ischemic stroke involve restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics is limited due to the therapeutic window of \< 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy. Following the completion of a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy.

Allogeneic mesenchymal stem cells have been used in a number of clinical trials for different indications demonstrated the safety of allogeneic mesenchymal stem cell treatment. In addition to their ability to differentiate into multiple different cell types that would be contributory to the recovery and repair of the brain by replacing destroyed cells, mesenchymal stem cells also secrete angiogenins, cytokines and trophic factors that can support and stimulate multiple other cell types. The cascade of cellular events following the release of these cytokines and trophic factors would also potentially lead to beneficial effects by restoring blood supply, by rescuing cells at risk, and by stimulating the remaining cell populations to repair and propagate new cells and synaptic connections.
Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21 and rituximab IV on days 1, 8, 15, and 22 of cycle 2 and day 1 of subsequent cycles. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
The present disclosure provides a linkage model-based motion measuring method. The two-dimension image dataset acquiring step is to obtain a two-dimension image dataset. The skin position acquiring step is to obtain an original skin position and a measured skin position. The three-dimension image dataset acquiring step is configured to shoot the tested portion to obtain a three-dimension image dataset. The registration step is to exert the similarity measure optimization for the two-dimension image dataset and the three-dimension image dataset registration such that outer-level variables and inner-level variables can be obtained. Subsequently, the registration step is to minimize e<SP>2</SP>kj + [Sigma]iwid<SP>2</SP>I to obtain updated inner-level variables and exert the similarity measure optimization for the two-dimension image dataset and the three-dimension image dataset registration by using the outer-level variables and the updated inner-level variables to recalculate the similarity matric to update the outer-level variables and the inner-level variables. Therefore, the accuracy of the two-dimension image dataset and three-dimension image dataset registration can be increased.
The current challenge in effectively treating atrial fibrillation (AF) stems from a limited understanding of the intricate structure of the human atria. The objective and quantitative interpretation of the right atrium (RA) in late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) scans relies heavily on its precise segmentation. Leveraging the potential of artificial intelligence (AI) for RA segmentation presents a promising solution. However, the successful implementation of AI in this context necessitates access to a substantial volume of annotated LGE-MRI images for model training. In this paper, we present a comprehensive 3D cardiac dataset comprising 50 high-resolution LGE-MRI scans, each meticulously annotated at the pixel level. The annotation process underwent rigorous standardization through crowdsourcing among a panel of medical experts, ensuring the accuracy and consistency of the annotations. Our dataset represents a significant contribution to the field, providing a valuable resource for advancing RA segmentation methods.
Epidural steroid injections have long had an impact in the treatment of various spine-related conditions, particularly radiculopathy. The efficacy of epidural spinal injections has been attributed to the anatomic location reached by the injectate. Cervical epidural steroid injections are also used as an injury location indicator. This application is based on documenting pain relief after injection into a specific location in the cervical spine. Both the diagnostic and therapeutic applications for epidurals assume that the injectate remains local to the injection site in order to have its effects. However, in a recently completed study, the investigators group documented substantial diffusion of injectate after lumbar epidurals used computerized tomography (CT) assessments.1 Based on the exposure to ionizing radiation associated with CT along with the superior imaging specificity and sensitivity of MRI, the investigators are shifting their imaging modality to MRI for future studies. The proposed study is designed to evaluate the use of gadolinium and MRI to assess nature and amount of diffusion of injectate in the cervical region after standard-of-care epidural injections. To the investigators knowledge, this will be the first study to critically assess this common procedure in order to evaluate safety and efficacy in a clinical setting.
FIELD: medicine. ^ SUBSTANCE: present invention refers to a thermochromic material for dental models able to discolour reversibly depending on temperature whereat specified material is kept, to a method for making and applying thereof. The specified material contains a two-component silicone composition consisting of a silicon composition A - a catalyst, and a silicon composition B - a base combined with an effective amount of at least one thermochromic pigment discolouring in the temperature range 0C to 40C. The thermochromic pigment can be chosen from indirectly thermochromic composite materials, liquid crystal cholesterol derivatives, polythiophenes. Two or more thermochromic pigments discolouring at various temperatures can be used. The material is made by homogeneous dispersion of the thermochromic pigment or a mixture of such pigments in at least one of compositions (A) and (B). An impression technique involves making the specified material, placing of the prepared mixture in a patient's mouth and waiting for required discoloration of said mixture. ^ EFFECT: use of the offered material allows obtaining real-time information concerning temperature of the material for dental modeling after being placed in a patient's mouth that is effective for estimating the optimum impression operation length, and for changing the lengths of various required manipulations in the mouth associated with impression. ^ 14 cl, 7 ex, 3 dwg
PURPOSE:The titled pharmaceutical, having a mucosa adhesive film and an adhesive coated sheet in a laminated structure, capable of controlling the release of a chemical, preventing the swelling of the application drug by water permeated from the outer edge parts, and having improved adhesive property. CONSTITUTION:An application drug obtained by applying an adhesive 3, e.g. rubber based adhesive, acrylic adhesive or silicone based adhesive, containing a chemical or no chemical onto a base material 1, e.g. collagen, paper or PE film, and laminating a filmy mucosa adhesive 4, e.g. carboxymethyl cellulose (CMC), hydroxyethyl cellulose or gelatin, containing the chemical or no chemical, to the formed sheet. The adhesive coated sheet part larger than the mucosa adhesive layer is capable of suppressing the swelling of the outer edge parts in application and improving further the adhesive property. A chemical for treating aphtha in the mouth, inhibitor for toothache, remedy for angina pectoris, etc. is used as the chemical, and mainly applied to the mucosa of the oral cavity, pudendum part, etc.
This is a prospective, multicenter, randomized controlled clinical study. A total of 36 patients with locally advanced esophagogastric conjoint adenocarcinoma without any treatment and resection were included in this study. After signing informed consent and meeting the screening criteria, a total of 36 patients were randomized into the observation group and the control group (18 cases and 18 cases, respectively) without blindness. Other participants include the Second Affiliated Hospital of Air Force Medical University, Henan Provincial People's Hospital, Cancer Hospital of Tianjin Medical University, Zhongshan Hospital Affiliated to Shanghai Fudan University, and the First Affiliated Hospital of Xi 'an Jiaotong University. The research groups were as follows: patients with resectable gastroesophageal conjunctive adenocarcinoma were randomly divided into observation group and control group. The observation group received preoperative nabuliumab combined with FLOT and trastuzumab + surgical treatment + postoperative nabuliumab combined with FLOT and trastuzumab. The control group was treated with preoperative FLOT combined with trastuzumab + surgical treatment + postoperative FLOT combined with trastuall Zumab. Preoperative and postoperative cycles were 4 in both groups, with one cycle every 2 weeks. Specific administration was as follows: Docetaxel 50mg/m2 iv,d1, oxaliplatin 85mg/m2 iv,d1, calcium leucovorin 200mg/m2 iv,d1,5-FU 2600mg/m2 iv,d1, infusion 24h; Nebulizumab 240mg iv,d2, 30 minutes per intravenous infusion, trastuzumab 4mg/kg iv,d2 (load dose 6mg /kg). At 3-4 weeks after the completion of the last dosing cycle, the efficacy of neoadjuvant therapy and the possibility of radical resection were evaluated in combination with preoperative imaging examination, and radical surgical treatment was performed. After the operation, the investigator will determine whether to carry out adjuvant treatment and choose the appropriate treatment plan (the first treatment should start from 3-6W after the operation and should not exceed 3 months). After 4 cycles of adjuvant therapy, the observation group was treated with nebuliumab combined with trastuzumab, and the control group was treated with trastuzumab maintenance therapy, with 10 cycles for each The specific administration was as follows: 240mg iv,d1, intravenous infusion for 30 minutes each time; Trastuzumab 4mg/kg intravenously. Resection of esophagogastric junction carcinoma was performed based on the 2023 Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and treatment of gastric cancer.
The present invention provides a gene encoding truncated human keratinocyte growth factor. The gene is any one selected trom the group consisting of, 1) the sequence of SEQ ID No: i in the sequence list; 2) a DNA sequence having a sequence honology of 90% or more to the DNA sequence of SEQ ID No: I and encoding proteins with the same functions as that encoded by SEQ ID No: L Also provided is a method of preparing a truncated human keratinocyte growth factor, comprising the following Steps: (1) preparation of plasmids by using a sequence of a fusion gene of a truncated human keratinecyte growth factor and a mature signal peptide, prepared through artil total gene synthesis; (2) obtaining a product by the steps of fermentation. cultivation. induction and expression, The method according to the Oresent invention is simple and can efficiently express genetic recombinant truncated human keratinocyte growth factor. The expression quantity of the truncated hunan keratinocyte growth factor in a fermenter is 250mg /L or more, w hich is more than three times of that of the wild type. Figure I Drawing BamHI (933) .'AO 1 a-factor ig'KGFM3 NotI (1631) 3'AOX1(TT) pPIC9K- 'i-KG F A23 9672bp 3'A OX 1 -H SaI(3573) Figure 1 500~bp+ Figure 2
BACKGROUND: This study explored the correlation between peripheral blood lipid levels and clinicopathological parameters in patients with advanced gastric cancer (GC), focusing on changes in lipid levels during disease progression.
METHODS: Pathological features and serum lipid profiles of 179 patients with stage III-IV gastric adenocarcinoma were analyzed. Lipid parameters examined included total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein AI (Apo AI), apolipoprotein B (Apo B), lipoprotein(a) (Lp(a)), among others. The total cholesterol-lymphocyte score (TL score) and BMI were also calculated. The association between lipid parameters and clinicopathological characteristics such as age, gender, family history, and metastasis sites was assessed.
RESULTS: In GC patients, females had higher TG levels than males. Patients with peritoneal metastasis had significantly lower levels of TC, LDL-C, Apo B, and B/A ratio. Those with lung metastasis exhibited higher LDL-C levels and lower levels of VLDL-C. No significant associations were found between lipid levels and metastasis to distant lymph nodes, liver, or bone. Female patients with ovarian metastasis had significantly lower VLDL-C levels. Multivariate analysis revealed low TC as an independent risk factor for peritoneal metastasis, high LDL-C and low VLDL-C levels for lung metastasis, and younger age and low VLDL-C for ovarian metastasis.
CONCLUSION: Specific blood lipid levels are significantly associated with metastatic sites in advanced gastric cancer. Lipid profiles could serve as potential biomarkers for predicting metastatic sites in GC patients.
Participants are exposed to several words of emotional contents (positive, and negative). The differences between these words will allow the regulation and counter regulation of emotional processes (Schwager y Rothermund, 2013). The words are related to clinical and personal characteristics of the patients and they will promote an emotional identification that improve the emotional regulation (Kashdan, Barret y McKnight, 2015).
Deficiency of Vitamin D is highly prevalent in all sectors and regions of Pakistan. Its effects encompass multiple pluripotent physiological impacts on human body, including its classical action on bone health and immune modulation. Health care workers are routinely prescribing supplementations to correct the deficiencies. Different forms of Cholecalciferol are available in the market. It ranges from absorba liquids, drops, tablets, softgels to injectable and oral ampoules. Different delivery systems offer different advantages, challenges and efficacies specific to their specific pharmacokinetics. The aim of this study is to adapt the gold standard of research and to explore the comparative bioavailability and clinical efficacy of the two most commonly used forms of Cholecalciferol i.e. ampoules and softgel capsules.
PURPOSE:To obtain boehmite type aluminum hydroxide which is scarcely decomposed by enteric alkaline liquid or gastric acid by treating the surface of a specified boehmite type aluminum hydroxide with a specified sulfate. CONSTITUTION:Aimed boehmite type aluminum hydroxide expressed by the formula II (wherein 0.01<X<0.10; 0<=n<1) is obtd. by treating the surface of boehmite type aluminum hydroxide expressed by the formula I (wherein 0<=m<1) with sulfuric acid or a sulfate which generates sulfuric acid by heating or by hydrolysis. The surface treatment is achieved by adding sulfuric acid or aq. soln. of sulfate to an aq. suspension of boehmite raw material under stirring. The concn. of the raw material boehmite in the aq, suspension is usually ca.5-30wt.%. A dose of the boehmite is usually 3-6g per day for adult and is taken dividedly into 3-4 times.
PURPOSE: To enable the simple and speedy diagnosis of whether or not infected with Hantaan viruses by a reagent which contains sensitized insoluble grains obtained by sensitizing the Hataan viruses antigen to insoluble carrier grains. CONSTITUTION: Though a Hataan virus reagent can be prepared from the organs of infected animals, infected cultured cells, etc., it is preferable to be prepared from the brain of an infected suckling mouse or a rat in terms of yields, safety, etc. One of the methods to prepare from this brain of a suckling mouse or a rat is, e.g. as follows. The brain of a suckling mouse or a rat is inoculated and infected with the viruses. Tissue emulsion obtained from this infected brain tissue is centrifuged at a low temperature, the supernatant fluid is taken, and treated with ethyl alcohol and protamine sulfate. Then this is further centrifuged at high speed and the supernatant fluid is taken, the formalin left after inactivated with formalin is removed by dialysis, and the Hantaan virus antigen is obtained.
The research will be carried out with two groups as intervention and control groups. Sample size of the study has been determined by the power analysis, in line with the results obtained from the studies which have been conducted using a similar research method. According to the analysis results, it has been calculated as 27 for each group and 54 in total. Considering the possible case losses, 20% of the sample was increased. The sample consisted of 64 babies, 32 intervention and 32 control. Mothers of the infants meeting the study inclusion criteria will be informed both in written and verbally. Written consent will be obtained. The infants will be divided into two groups according to stratified block randomization in the computer environment. The infants will be stratified by gender and age. After the randomization, therapeutic touch will be applied to the intervention group. No method will be applied to the control group by the researcher. In obtaining research data, 4 tools will be used: "Mother-infant Information Form", "Infantile Colic Scale", Crying Time Registration Form and Sleep Time Registration Form.
The magnitude of plasma GLP-1 following an OGTT (75g glucose per os) when beta-hydroxybutyrate (BHB) is released either at an upper gastrointestinal site (alginate encapsulation), or at distal gastrointestinal site (pea-protein encapsulation). BHB is given per-os in a single dose of 18g, plus 2 g encapsulation material; totally 20 g.